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Editors: Anton N. Sidawy and Bruce A. PerlerProspective, multicenter experience with the Ventana
Fenestrated System for juxtarenal and pararenal aortic
aneurysm endovascular repair
William J. Quiñones-Baldrich, Andrew Holden, Renato
Mertens, Matt M. Thompson, Alan P. Sawchuk, Jean-Pierre
Becquemin, Matthew Eagleton, Daniel G. Clair
Objective: This study assessed preliminary results of the
Ventana Fenestrated System (Endologix, Irvine, Calif) as an
off-the-shelf integrated device for juxtarenal aortic aneur-
ysm (JAA) or pararenal aortic aneurysm (PAA) endovascular
repair.
Methods: From November 2010 to April 2012, seven cen-
ters enrolled 31 patients with JAAs or PAAs in an interna-
tional clinical trial of the Ventana Fenestrated System.
Clinical and laboratory evaluations were done predischarge
and at 1 month, with continuing follow-up through 5 years.
Core laboratory computed tomography imaging assess-
ments were performed at 1 month and at each subsequent
follow-up.
Results: Patients (mean, age 73 years; 90% male) presented
with mean aneurysm sac diameter of 6.0 cm. One patient
with a short, reversed tapered infra-superior mesenteric
artery (SMA) neck was enrolled under a protocol waiver.
Among the 31 patients, one of ﬁve Ventana device models
was used to preserve main renal arteries, the SMA, and
celiac arteries; 20 patients (65%) received the same Ven-
tana device (aligned fenestrations, 28-mm diameter).
Median ﬂuoroscopy and procedure times were 49 and 197
minutes, respectively; median hospital length of stay was
3.0 days. The 1-month clinical success rate was 94% (29 of
31), with no perioperative mortality. One intervention on
day 26 was done to resolve limb kink/occlusion. A type IA
endoleak and renal occlusion secondary to procedural
device damage led to a reintervention on day 52 and dial-
ysis at 5 months. During follow-up to 23 months, three non-
aneurysm-related deaths occurred. No aneurysm rupture or
conversion to open repair has occurred. One late migration
with endoleak and covered renal stent fracture/occlusion
occurred at 8 months in the patient with a short, reverse
tapered infra-SMA neck performed under a protocol waiver,
which was managed successfully with bilateral renal
bypasses and endovascular repair of the endoleak. Another
patient underwent late endovascular interventions to
resolve bilateral renal stenosis.*Full articles available online at www.jvascsurg.org
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http://dx.doi.org/10.1016/S1078-5884(13)00374-2Conclusions: The multicenter experience of the Ventana
Fenestrated System supports its safety and early-term to
midterm effectiveness for the endovascular repair of JAAs
and PAAs. This off-the-shelf integrated system permits
endovascular treatment of JAAs or PAAs; however, further
expanded clinical experience and longer-term follow-up are
needed to more fully assess this device system.Deﬁning a role for contrast-enhanced ultrasound in
endovascular aneurysm repair surveillance
Alistair Millen, Rana Canavati, Gareth Harrison, Richard G.
McWilliams, Steve Wallace, Srinivasa R. Vallabhaneni,
Robert K. Fisher
Objective: Endovascular aneurysm repair (EVAR) surveil-
lance includes duplex ultrasound, abdominal radiography,
and computed tomography angiography. Contrast-
enhanced ultrasound (CEUS) has emerged as an additional
modality whose role remains undeﬁned. We evaluated
whether a potential role for CEUS was the elucidation of
unresolved issues following standard surveillance
modalities.
Methods: All patients undergoing EVAR at a tertiary referral
center had surveillance based on plain abdominal radio-
graph and duplex ultrasound, with single arterial phase
computed tomography angiography reserved for abnor-
malities or nondiagnostic imaging. In this prospective
evaluation, from April 2010 to July 2011, discordance
between imaging modalities or unresolved surveillance
issues prompted CEUS. Cases and imaging were discussed in
a multidisciplinary setting and outcomes recorded.
Results: During the study period, 539 patients underwent
EVAR surveillance, of whom 33 (6%) had CEUS for unresolved
issues (median age, 79; range, 66-90; 28 male). Median fol-
low-up after EVAR was 23 months (range, 0-132). In all cases,
CEUS was able to resolve the clinical issue, resulting in sec-
ondary intervention in 10 patients (30%). The remaining
patients were returned to surveillance.Within the cohort of
33 patients, the clinical issues were categorized into three
groups. Group 1: Endoleak of uncertain classiﬁcation (n¼ 27:
21 type II, four type I, two had endoleak excluded). Group 2:
Signiﬁcant aneurysm expansion (5 mm) without apparent
endoleak (n ¼ 4: one type II, three had endoleak excluded).
Group 3: Target vessel patency following fenestrated EVAR
(n ¼ 2: patency conﬁrmed in both).
Conclusions: CEUS can enhance EVAR surveillance through
clariﬁcation of endoleak and target vessel patency when
standard imaging modalities are not diagnostic.
Abstracts 153Treatment of acute visceral aortic pathology with
fenestrated/branched endovascular repair in high-surgical-
risk patients
Salvatore T. Scali, Alyson Waterman, Robert J. Feezor, Tomas
D. Martin, Philip J. Hess, Thomas S. Huber, Adam W. Beck
Objective: The safety and feasibility of fenestrated/
branched endovascular repair of acute visceral aortic dis-
ease in high-risk patients is unknown. The purpose of this
report is to describe our experience with surgeon-modiﬁed
endovascular aneurysm repair (sm-EVAR) for the urgent or
emergent treatment of pathology involving the branched
segment of the aorta in patients deemed to have prohib-
itively high medical and/or anatomic risk for open repair.
Methods: A retrospective review was performed on all
patients treated with sm-EVAR for acute indications. Plan-
ning was based on three-dimensional computed tomo-
graphic angiogram reconstructions and graft conﬁgurations
included various combinations of branch, fenestration, or
scallop modiﬁcations.
Results: Sixteen patients (mean age [ standard deviation],
68 10 years; 88% male) deemed high risk for open repair
underwent urgent or emergent repair using sm-EVAR.
Indications included degenerative suprarenal or thor-
acoabdominal aneurysm (six), presumed or known mycotic
aneurysm (four), anastomotic pseudoaneurysm (three),
false lumen rupture of type B dissection (two), and pene-
trating aortic ulceration (one). Nine (56%) had previous
aortic surgery and all patients were either American Society
of Anesthesiologists class IV (n ¼ 9) or IV-E (n ¼ 7). A total
of 40 visceral vessels (celiac, 10; superior mesenteric artery,
10; right renal artery, 10; left renal artery, 10) were revas-
cularized with a combination of fenestrations (33), direc-
tional graft branches (six), and graft scallops (one).
Technical success was 94% (n ¼ 15/16), with one open
conversion. Median contrast use was 126 mL (range, 41-
245) and ﬂuoroscopy time was 70 minutes (range, 18-200).
Endoleaks were identiﬁed intraoperatively in four patients
(type II, n ¼ 3; type IV, n ¼ 1), but none have required
remediation. Mean length of stay was 12  15 days
(median, 5.5; range, 3-59). Single complications occurred in
ﬁve (31%) patients as follows: brachial sheath hematoma
(one), stroke (one), ileus (one), respiratory failure (one), and
renal failure (one). An additional patient experienced mul-
tiple complications including spinal cord ischemia (one) and
multiorgan failure resulting in death (n ¼ 1; in-hospital
mortality, 6.3%). The majority of patients were discharged
to home (63%; n ¼ 10) or short-term rehabilitation units
(25%; n ¼ 4), while one patient required admission to a
long-term acute care setting. There were no reinterventions
at a median follow-up of 6.2 (range, 1-16.1) months. Post-
operative computed tomographic angiogram was available
for all patients and demonstrated 100% branch vessel
patency, with one type III endoleak pending intervention.
There were two late deaths at 1.4 and 13.4 months due to
nonaortic-related pathology.
Conclusions: Urgent or emergent treatment of acute
pathology involving the visceral aortic segment withfenestrated/branched endograft repair is feasible and safe
in selected high-risk patients; however, the durability of
these repairs is yet to be determined.The United States StuDy for EvalUating EndovasculaR
TreAtments of Lesions in the Superﬁcial Femoral Artery
and Proximal Popliteal By usIng the Protégé EverfLex
NitInol STent SYstem II (DURABILITY II)
Jon S. Matsumura, Dai Yamanouchi, Jeffrey A. Goldstein,
Christopher W. Pollock, Marc Bosiers, Greg A. Schultz, Dierk
Scheinert, Krishna J. Rocha-Singh
Objective: Angioplasty and stenting are options for revas-
cularization of symptomatic femoral popliteal disease.
Although angioplasty alone is effective in short lesions,
longer lesions are often treated with stents. Multiple
overlapping stents are expensive and may be associated
with stent fracture. This trial evaluated the safety and efﬁ-
cacy of a single self-expanding stent up to 20 cm in length in
patients with atherosclerotic disease of the superﬁcial
femoral artery (SFA) and proximal popliteal artery.
Methods: Patients with lesions >4 cm and <18 cm were
enrolled in this nonrandomized, prospective,multicenter trial
that evaluated the Protégé EverFlex Self-Expanding Periph-
eral Stent System (Covidien, Plymouth, Minn). The study’s
primary end points were the 30-daymajor adverse event rate
and duplex ultrasound-assessed patency at 1 year. These
were compared with published performance goals. A pre-
planned analysis was conducted for the primary effectiveness
end points at 1 year. Follow-up, including history, ankle-bra-
chial index, patient-reported outcomes, duplex ultrasound
assessment, and radiographs, is planned through 3 years.
There was core laboratory review of angiograms, ultrasound
scans, and plain radiographs. A subgroup of patients was
studied with graded treadmill testing.
Results: The study enrolled 287 patients (66% male; mean
age, 68 years) with stenotic, restenotic, or occluded lesions
of the SFA at 44 investigational sites in the United States
and Europe. Systemic comorbidities included hypertension
(88%), hyperlipidemia (86%), diabetes (43%), and prior SFA
intervention (41%). The mean lesion length measured by
the core laboratory was 89 mm. The mean normal-to-nor-
mal lesion length measured by sites was 110 mm. A total of
303 stents were implanted, and 95% of patients received a
single stent. No major adverse events occurred at 30 days.
At 1 year, primary outcome of duplex ultrasound stent
patency was 67.7% in evaluable patients, and among 1-year
secondary outcomes, the mean ankle-brachial index
increased by 0.25. Walking Improvement Questionnaire
scores improved in pain by 33.7, distance by 37.1, speed by
18.6, and stair climbing by 24.7. The Kaplan-Meier estimate
of primary patency was 77.2%, primary assisted patency
was 86.9%, and secondary patency was 87.3%. Rutherford
clinical category improved in 83.5% of patients. Stent frac-
ture rate was 0.4%. Matched absolute claudication distance
was 412 feet greater and was not statistically different in
this subgroup of 29 individuals.
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ating EndovasculaR TreAtments of Lesions in the Superﬁcial
Femoral Artery and Proximal Popliteal By usIng the Protégé
EverfLex NitInol Stent SYstem II) suggest that a new single
stent strategy is safe and effective for the treatment of long
lesions of the SFA and proximal popliteal arteries at 1 year.Vasospasm as a cause for claudication in athletes with
external iliac artery endoﬁbrosis
Sherene Shalhub, R. Eugene Zierler, Watson Smith, Kari
Olmsted, Alexander W. Clowes
Background: Exercise-induced external iliac artery endoﬁb-
rosis (EIAE) is rare and has been described primarily in
endurance male cyclists. Clinically, it presents as claudica-
tion during maximal exercise with quick resolution after
exercise. Most patients have ﬁbrotic changes within the
external iliac artery (EIA). We describe our experience with
EIAE and propose a hypothesis for the mechanism involved
in the associated claudication.
Methods: This was a retrospective review of athletes who
presented with symptomatic EIAE requiring operative repair
between 2001 and 2010. Data collected included demographic
information, initial presentation, type of exercise, repair, and
long-term outcome. Diagnostic studies consisted of duplex
evaluation, modiﬁed exercise treadmill test, and angiography.
Results: Eight women, presented with symptomatic EIAE. Two
had bilateral EIAE. All were endurance athletes (three cyclists,
one runner, and four were cyclists and runners).Median age at
presentation was 42.5 years (range, 39-60 years). Median
duration of symptoms was 5.5 years (range, 2-15 years).
Diagnosis was conﬁrmed with an exercise treadmill test
modiﬁed to accommodate these patients’ high level of con-
ditioning and unmask the claudication. In the most recent two
patients, marked EIA vasospasm was noted after exercise by
duplex scanning. All patients were treated with EIA vein patch
angioplasty. Follow-up ranged from 1 to 10 years. All had a
normal result on the modiﬁed exercise treadmill test and
resumed their athletic activities postoperatively.
Conclusions: This series highlights a possible mechanism to
explain the claudication associated with EIAE. Vasospasm
may be more important than wall thickening for the
reduction of blood ﬂow during extreme exercise in affected
athletes. Routine duplex ultrasound imaging to measure EIA
diameter and ﬂow velocities before and after maximal
exercise is needed to conﬁrm this phenomenon.Optimal selection of asymptomatic patients for carotid
endarterectomy based on predicted 5-year survival
Jessica B. Wallaert, Jack L. Cronenwett, Daniel J. Bertges,
Andres Schanzer, Brian W. Nolan, Randall De Martino,
Jens Eldrup-Jorgensen, Philip P. Goodney
Objective: Although carotid endarterectomy (CEA) is per-
formed to prevent stroke, long-term survival is essential to
ensure beneﬁt, especially in asymptomatic patients. Weexamined factors associated with 5-year survival following
CEA in patients with asymptomatic internal carotid artery
(ICA) stenosis.
Methods: Prospectively collected data from 4114 isolated
CEAs performed for asymptomatic stenosis across 24 cen-
ters in the Vascular Study Group of New England between
2003 and 2011 were used for this analysis. Late survival was
determined with the Social Security Death Index. Cox pro-
portional hazard models were used to identify risk factors
for mortality within the ﬁrst 5 years after CEA and to cal-
culate a risk score for predicting 5-year survival.
Results: Overall 3- and 5-year survival after CEA in asymp-
tomatic patients were 90% (95% CI 89%-91%) and 82% (95%
CI 81%-84%), respectively. By multivariate analysis, increas-
ing age, diabetes, smoking history, congestive heart failure,
chronic obstructive pulmonary disease, poor renal function
(estimated glomerular ﬁltration rate <60 or dialysis
dependence), absence of statin use, and worse contralateral
ICA stenosis were all associated with worse survival. Patients
classiﬁed as low (27%), medium (68%), and high risk (5%)
based on number of risk factors had 5-year survival rates of
96%, 80%, and 51%, respectively (P < .001).
Conclusions: More than four out of ﬁve asymptomatic
patients selected for CEA in the Vascular Study Group of
New England achieved 5-year survival, demonstrating that,
overall, surgeons in our region selected appropriate
patients for carotid revascularization. However, there were
patients selected for surgery with high risk proﬁles, and our
models suggest that the highest risk patients (such as those
with multiple major risk factors including age 80, insulin-
dependent diabetes, dialysis dependence, and severe con-
tralateral ICA stenosis) are unlikely to survive long enough
to realize a beneﬁt of prophylactic CEA for asymptomatic
stenosis. Predicting survival is important for decision mak-
ing in these patients.The current national criteria for carotid artery stenting
overestimate its efﬁcacy in patients who are symptomatic
and at high risk
Shunsuke Yoshida, Rodney P. Bensley, Julia D. Glaser,
Christoph S. Nabzdyk, Allen D. Hamdan, Mark C. Wyers,
Elliot L. Chaikof, Marc L. Schermerhorn
Background: The Centers forMedicare andMedicaid Services
(CMS) have established guidelines that outline patients who
are considered “high risk” for complications after carotid
endarterectomy (CEA) for which carotid artery stenting (CAS)
may provide beneﬁt.The validity of these high-risk criteria are
yet unproven. In this study, we stratiﬁed patients who
underwent CAS or CEA by CMShigh-risk criteria and symptom
status and examined their 30-day outcomes.
Methods: A nonrandomized, retrospective cohort study was
performed by chart review of all patients undergoing CEA or
CAS from January 1, 2005, to December 31, 2010, at our
institution. Demographic data and data pertaining to the
presence or absence of high-risk factors were collected.
Patients were stratiﬁed using symptom status and high-risk
Abstracts 155status as variables, and 30-day adverse events (stroke,
death, myocardial infarction [MI]) were compared.
Results: A total of 271 patients underwent CAS, with 30-day
complication rates of stroke (3.0%), death (1.1%), MI (1.5%),
stroke/death (3.7%), and stroke/death/MI (5.2%). A total of
830 patients underwent CEA with 30-day complication rates
of stroke (2.0%), death (0.1%), MI (0.6%), stroke/death
(1.9%), and stroke/death/MI (2.7%). Among symptomatic
patients, physiologic high-risk status was associated with
increased stroke/death (6 of 42 [14.3%] vs 2 of 74 [2.7%]; P<
.01), and anatomic high-risk status was associated with a
trend toward increased stroke/death (5 of 31 [16.1%] vs 0 of
20 [0.0%]; P ¼ .14) in patients who underwent CAS vs CEA.
Analysis of asymptomatic patients showed no differences
between the two groups overall, except for a trend toward a
higher rate of MI after CAS than after CEA (3 of 71 [4.2%] vs 0
of 108 [0.0%]; P ¼ .06) in those who were physiologically at
high risk. Among symptomatic patients who underwent CAS,
patientswith physiologic and anatomic high-risk factors had a
higher rate of stroke/death than non-high-risk patients (6 of
42 [14.3%] vs 0 of 24 [0.0%] and 5 of 31 [16.1%] vs 0 of 24
[0.0%], respectively; both P  .05).
Conclusions: Physiologic high-risk status was associated
with increased stroke/death, whereas anatomic high-risk
status showed a trend toward increased stroke/death in
symptomatic patients undergoing CAS compared with non-
high-risk patients undergoing CAS or physiologically high-
risk patients undergoing CEA. Our results suggest that the
current national criteria for CAS overestimate its efﬁcacy in
patients who are symptomatic and at high risk.Contemporary outcomes after distal vertebral
reconstruction
Dawn M. Coleman, Andrea Obi, Enrique Criado, Shipra Arya,
Ramon Berguer
Introduction: Flow-limiting lesions or embolic phenomena
can produce vertebrobasilar ischemia. This study aims todifferentiate the pathophysiology of vertebral ischemia and
examine contemporary outcomes after distal vertebral
reconstruction.
Methods: Between February 2005 and November 2011, 41
consecutive distal vertebral artery (VA) reconstructions
were performed in 34 patients, including bypass to the third
portion of the VA (V3) at the C1-2 level (n ¼ 24) or the C0-1
level (n ¼ 7); transposition of the external carotid artery or
its occipital branch onto V3 (n ¼ 6); transposition of V3
onto the internal carotid artery (n ¼ 3); and bypass from
the ipsilateral subclavian artery to V3 (n ¼ 1). Six patients
required a concomitant carotid intervention, and nine
patients required a partial resection of the C1 transverse
process. Symptoms, present in 91% of patients, were
attributed to a ﬂow-limiting lesion in 16 (52%), to emboli-
zation in nine (29%), and to a mixed etiology in six (19%).
Results: Intraoperatively, ﬁve patients required graft revi-
sion or conversion of a transposition to a bypass, and two
patients required vertebral ligation. Median blood loss was
260 mL. Median hospital length of stay was 1 day. Post-
operatively, one patient (2%) required re-exploration for
bleeding, a stroke occurred in one patient (2%), and cranial
nerve injury occurred in three patients (7%). There were no
perioperative deaths. Survival analysis showed that primary
patency at 1, 2, and 5 years, respectively, was 74%, 74%,
and 54%. Secondary patency was 80% at 1 year and
remained so through the end of follow-up at 80 months. A
statistically signiﬁcant difference in patency was noted
favoring arterial transposition over vertebral bypass of
100%, 100%, and 83% at 1, 2, and 5 years, respectively, vs
65%, 65%, and 39% (P ¼ .018). Considering successful redo
bypass grafting for late failure, 97% of patients demon-
strated preserved patency at their last follow-up. There
were two late deaths of unknown etiology and no late
strokes.
Conclusions: Distal VA reconstruction for ﬂow-limiting or
embolic lesions provides excellent stroke protection and
symptomatic relief with acceptable perioperative risk in
selected patients.
